Natco Pharma share climbs 7% as firm seeks nod for COVID-19 drug
Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication, according to a press release from Natco
Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO seeks Emergency approval of Molnupiravir capsules for Covid-19 treatment NATCO PHARMA LTD. - 524816 - Non - Applicability Of SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 Dated November 26, 2018 - Fund Raising By Issuance Of Debt Securities By Large Entities
Non - applicability of SEBI circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018 - Fund Raising by issuance of debt securities by Large Entities Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO receives tentative approval for Ibrutinib tablets (generic for IMBRUVICA (r)) ANDA in the US market Natco Pharma Ltd - 524816 - Compliance Certificate For The Half Year Ended March 31, 2021
Compliance Certificate for the half year ended March 31, 2021 Natco Pharma Ltd - 524816 - Shareholding for the Period Ended March 31, 2021
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here Natco Pharma Ltd - 524816 - Reg 40(10) PCS Certificate For The Half Year Ended March 31, 2020
Reg 40(10) PCS certificate for the half year ended March 31, 2020 NATCO PHARMA LTD. - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2021 Natco Pharma Ltd - 524816 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- M ADINARAYANADesignation :- Company Secretary and Compliance Officer Natco Pharma Ltd - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of Loss of Certificates